Woman with curly hair smiling in a workshop surrounded by woodworking tools.

Actor portrayal

Products & Innovation

The portfolio centered on CNS cancers.

Cerenome’s portfolio is built entirely for central nervous system (CNS) cancers. It spans a diagnostic already in the clinic and an investigational therapy in active trials, with a pipeline behind them, each one an expression of the same integrated platform.

The Portfolio

How our portfolio holds together.

Cerenome’s products are being engineered as one integrated platform, so they reinforce each other: the diagnostic informs the therapy, and the response to treatment feeds data back into both. Where many companies in CNS oncology advance a single product, Cerenome’s portfolio elevates every product within it.

One Integrated Platform

Diagnosis shapes treatment

Diagnostics

CNSide®

Therapeutics

REYOBIQ™

Data Insights

Intelligence layer

Detection becomes data

Response becomes evidence

CNSide®

In the clinic today.

A commercial cerebrospinal fluid diagnostic platform designed to detect, characterize, and monitor cancer in the CNS through cellular and molecular testing, including tumor cell enumeration and next-generation sequencing. Testing is performed in a CLIA-certified, CAP-accredited laboratory.

REYOBIQ™

In active trials.

An investigational rhenium-186 radiotherapeutic, encapsulated in a nanoliposome designed to hold a targeted dose at the tumor. Its gamma emission lets the dose be imaged as it’s delivered while its beta emission attacks the cancer cells.

Where REYOBIQ™ is tested

The active clinical trials.

The ReSPECT™ program, evaluating REYOBIQ™ across recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.

Man in a pink button-down shirt speaking during an interview in a bright, modern lounge.

Inside the portfolio.

Cerenome’s CEO, Marc Hedrick, MD, on the pipeline behind the platform, and how what’s commercial today connects to what’s still in development.

The milestones behind the portfolio.

The portfolio is backed by concrete milestones. The Phase 1 results of REYOBIQ™ in recurrent glioblastoma are published in Nature Communications. CNSide® is in clinical use, accredited, and reimbursed. Two ReSPECT™ trials are enrolling, funded by the National Cancer Institute (NCI), Cancer Prevention and Research Institute of Texas (CPRIT), and the U.S. Department of Defense (DoD).